imazodan has been researched along with n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coates, WJ; Prain, HD; Reeves, ML; Warrington, BH | 1 |
| Beedle, EE; Hayes, JS; Kauffman, RF; Krushinski, JH; Pollock, GD; Robertson, DW; Wilson, H; Wyss, V | 1 |
2 other study(ies) available for imazodan and n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide
| Article | Year |
|---|---|
1,4-bis(3-oxo-2,3-dihydropyridazin-6-yl)benzene analogues: potent phosphodiesterase inhibitors and inodilators.
Topics: Animals; Cats; Female; Male; Phosphodiesterase Inhibitors; Pyridazines; Vasodilator Agents | 1990 |
Dihydropyridazinone cardiotonics: the discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H -indol-2- one.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Cats; Dogs; Female; In Vitro Techniques; Indoles; Male; Myocardial Contraction; Oxindoles; Platelet Aggregation; Pyridazines; Structure-Activity Relationship | 1986 |